Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.
- Revenue rises 11% to $3.06 million
- Net loss increases 11% to $3.72 million
- Higher operating expenses driven by R&D and compliance
- New subsidiary OsteoRx Pte Ltd established in Singapore
- Convertible notes underpin going concern and capital structure
Revenue Growth Amid Strategic Investment
Osteopore Limited, a regenerative medicine company listed on the ASX, has reported an 11% increase in revenue for the year ended 31 December 2025, reaching a record $3.06 million. This growth reflects stronger market traction across its core regions, including Singapore, Korea, China, and Australia, and highlights the company’s ongoing efforts to commercialise its innovative product portfolio.
Despite this top-line expansion, Osteopore’s net loss after tax widened by 11% to $3.72 million, up from $3.35 million the previous year. The increased loss is primarily attributed to higher operating expenses, notably in product development and laboratory activities, as well as expanded compliance costs associated with regulatory readiness and broader commercial deployment.
Investing for Long-Term Growth
The company’s elevated expenditure underscores a strategic commitment to advancing its regenerative medicine technologies and entering new markets. Osteopore’s management emphasised that these investments are essential for sustainable commercial scale and future profitability, even as they pressure near-term earnings.
Operating expenses rose significantly, with product development and laboratory costs leading the increase. Additionally, the company recognised a higher expected credit loss provision, reflecting prudent credit risk management amid its expanding customer base.
Capital Structure and Going Concern
Osteopore’s balance sheet shows a net asset deficiency of $1.73 million, largely due to outstanding redeemable convertible notes valued at approximately $2.65 million as of year-end. These notes, issued under a subscription agreement with Advance Opportunities Fund, provide a vital funding mechanism, with $800,000 converted into equity shortly after the reporting period.
The company’s cash position stood at $627,000, supported by ongoing capital management and share placements that increased issued capital to over 272 million shares. The board remains confident in the company’s ability to continue as a going concern, contingent on achieving forecasted sales growth, managing costs, and accessing further funding if necessary.
Expansion in Singapore and Market Outlook
During 2025, Osteopore incorporated a new wholly owned subsidiary, OsteoRx Pte Ltd, in Singapore, signalling a strategic push to strengthen its presence in the Asia-Pacific region. This move aligns with the company’s focus on key growth markets and regulatory compliance across multiple jurisdictions.
While the widened loss and net asset deficiency present challenges, Osteopore’s revenue momentum and investment in innovation position it for potential upside as commercialisation efforts mature. The company has not declared dividends, reflecting its reinvestment strategy and capital preservation focus.
Bottom Line?
Osteopore’s 2025 results highlight a classic growth-versus-profit trade-off, with investors watching closely for signs that its strategic investments will translate into sustainable profitability.
Questions in the middle?
- How will Osteopore manage its net asset deficiency amid ongoing losses?
- What impact will the new Singapore subsidiary have on regional sales and regulatory approvals?
- Can the company secure additional funding to support its growth trajectory beyond convertible notes?